top of page

From Feedstock to
Cancer Therapy

How the IsoMedica
Process Works

Through IsoMedica, entX is developing an integrated process to recover, purify and convert radioisotopes for use in advanced cancer therapies. The process brings together specialised chemistry, production technology and purpose-built infrastructure across three key stages.

WATCH THE FULL interview

Watch the extended video to learn how IsoMedica is helping secure the future of medical isotope supply and radiopharmaceutical innovation.

entX_IsoMedica-Webinar-Cover2.png

Three Stages of Medical Isotope Production

1. Extraction

The process begins with radium-bearing materials sourced through entX's partners, including streams that would otherwise require radiation management and disposal. entX extracts radium-228 from these materials to create the feedstock for downstream isotope production.

​

2. Purification

Using proprietary purification technology, entX separates radium-228 from other materials to achieve the chemical purity and specific activity required by customers. Consistent, high-quality purification is essential to meeting pharmaceutical-grade specifications and supporting reliable isotope supply.

 

3. Ingrowth and Conversion

The purified radium-228 naturally decays into thorium-228, which is recovered over time through a process known as milking. The thorium-228 is then used in a generator system to produce lead-212, an alpha-emitting radioisotope used in the development of targeted cancer therapies.

The Infrastructure Behind Commercial Production

The process will operate within entX's Advanced Radioisotope Manufacturing Facility (ARMF), designed to support safe, consistent and scalable radioisotope production.

​

Purpose-built infrastructure includes shielded hot cells, automated dispensing and packaging systems, radiation monitoring, analytical capabilities and quality management systems. The facility operates under regulatory approvals from the South Australian Environment Protection Authority (EPA).

 

These requirements represent significant barriers to entry, involving substantial capital investment, specialist regulatory expertise, technical infrastructure and a highly trained workforce.

​

By bringing together the technology, infrastructure and expertise required for each stage of production, entX is developing an integrated platform to support the growing demand for lead-212 and other medical radioisotopes.

An Integrated Capability in South Australia

By bringing feedstock access, proprietary technology and dedicated production infrastructure together, entX is developing an integrated medical isotope supply platform designed to support more secure and reliable isotope supply.

​

Combining South Australia's established resources and healthcare capabilities, the Mines to Medicines model provides a distinctive foundation for entX's ambitions in the global medical isotope market.

OTher Projects

Medical Isotopes

212-Pb

Supply chain process for the manufacture of Lead-212 radiopharmaceuticals

Space & Defence

RHU

Generating heat for critical electronics and lithium batteries to survive the extreme low temperatures of the lunar night.

Space & Defence

GEN X

Maintenance-Free, long term Power for unmanned, remote and challenging Space and Defence applications.

bottom of page